HomeB1NT34 • BVMF
add
BioNTech
Nakaraang pagsara
R$34.35
Sakop ng araw
R$33.60 - R$34.45
Sakop ng taon
R$26.80 - R$49.05
Market cap
23.34B USD
Average na Volume
666.00
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (EUR) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 182.80M | -2.56% |
Gastos sa pagpapatakbo | 593.40M | -6.05% |
Net na kita | -415.80M | -31.96% |
Net profit margin | -227.46 | -35.43% |
Kita sa bawat share | -1.73 | -32.06% |
EBITDA | -451.60M | 2.84% |
Aktuwal na % ng binabayarang buwis | 6.65% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (EUR) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 14.11B | -9.94% |
Kabuuang asset | 21.18B | -4.83% |
Kabuuang sagutin | 2.26B | -1.43% |
Kabuuang equity | 18.93B | — |
Natitirang share | 240.39M | — |
Presyo para makapag-book | 0.44 | — |
Return on assets | -5.65% | — |
Return on capital | -6.36% | — |
Cash Flow
Net change in cash
| (EUR) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -415.80M | -31.96% |
Cash mula sa mga operasyon | -780.70M | -146.04% |
Cash mula sa pag-invest | 1.25B | 154.11% |
Cash mula sa financing | -13.80M | -76.92% |
Net change in cash | 423.00M | 115.74% |
Malayang cash flow | -1.37B | -175.36% |
Tungkol
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
CEO
Itinatag
2008
Website
Mga Empleyado
6,772
